MDS Pharma Services adds John H. Dillon II as Senior Vice President
(Montreal, Quebec, February 8, 2001) — MDS Pharma Services is pleased to announce the addition of John Dillon II to its executive team. Dillon will serve as a senior vice president and operate from the organization's office in Philadelphia, Pa. His immediate responsibilities will be to enhance client relationships, construct strategic partnerships, and act as a customer advocate during the drug discovery and development process.
Dillon is a senior executive with more than 35 years of experience in the pharmaceutical industry. Before joining MDS Pharma Services, he served as a senior vice president, sales and marketing, for Accurian. His background also includes several years with IBAH, where he served first as senior vice president, corporate development, and then as executive vice president. While with IBAH, Dillon managed the functions of corporate development, worldwide business development, and worldwide marketing. He oversaw the acquisition and integration of three companies and helped IBAH establish new offices in Japan, Australia and Singapore. He also served for more than 20 years with SmithKline Beecham, ultimately holding the position of vice president and director of worldwide business development. Prior to entering the pharmaceutical industry, Dillon served four years in the Navy Medical Service Corps. Dillon's education background includes an M.B.A. from the Wharton School, University of Pennsylvania, Philadelphia, as well as a B.A. in history from Lafayette College.
In addition to his professional responsibilities, he has devoted time to numerous professional and civic organizations. While working with SmithKline Beecham, he also served as vice chairman and chairman of the National Pharmaceutical Council, an industry-wide body chartered to address issues of common interest to the pharmaceutical industry. For the Wharton School, Dillon served two years as president of the alumni association, and later, two years as chairman. He has also served as a member of the Dean's Advisory Board.
"We are extremely pleased to have John join our team," said Ian Lennox, president and CEO, MDS Pharma Services. "His extensive experience in business development within the pharmaceutical industry will help us develop creative strategies for forging strong, long-term relationships with our clients."
MDS Pharma Services offers a full spectrum of resources to meet customers' overall drug discovery and development needs. A global full-services partner with facilities in more than 17 countries, six units work together: discovery, preclinical, early clinical research (phases I-IIa), bioanalytical, global clinical research (phases IIb-IV), and central lab.
MDS Inc. (TSE: MDS; NYSE: MDZ), parent company of MDS Pharma Services, is an international health and life sciences company. In many of its products and services, it is among the largest and most respected companies in the world. At MDS, the focus is on fighting disease. It does this by providing laboratory testing, imaging products, research services to speed discovery and development of new drugs, therapy systems for planning and delivery of cancer treatments, analytical instruments to assist in the development of new drugs, and medical/surgical supplies. MDS employs more than 11,000 highly skilled people in its global operations on five continents.
Detailed information about the organization is available at the MDS Web site at www.mdsintl.com or by calling 1-888-MDS-7222, 24 hours a day.
